ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Fine on Capecitabine Plus Temozolomide for NETs

Robert L. Fine, MD,
Published: Friday, Jan 17, 2014



Robert L. Fine, MD, an associate professor of Medicine at New York Presbyterian Hospital-Columbia University Medical Center, discusses the prospective phase II study of CAPTEM (capecitabine and temozolomide) for patients with neuroendocrine tumors.

Fine says the results of the trial showed tremendous responses in every neuroendocrine tumor. The treatment elicited a response rate of 45% and a stable disease rate of 52%.

Carcinoids, which represents that majority of all neuroendocrine tumors and normally have a response rate of 0%-4%, showed a 45% response rate in this study, Fine says.

Moreover, Fine points out, the CAPTEM combination is extremely nontoxic. There were no grade 4 toxicities and only 10-15% grade 3 toxicities, with the most common grade 3 toxicity being lymphopenia.

Read more about this study >>>

<<< View more from the 2014 GI Cancers Symposium



Robert L. Fine, MD, an associate professor of Medicine at New York Presbyterian Hospital-Columbia University Medical Center, discusses the prospective phase II study of CAPTEM (capecitabine and temozolomide) for patients with neuroendocrine tumors.

Fine says the results of the trial showed tremendous responses in every neuroendocrine tumor. The treatment elicited a response rate of 45% and a stable disease rate of 52%.

Carcinoids, which represents that majority of all neuroendocrine tumors and normally have a response rate of 0%-4%, showed a 45% response rate in this study, Fine says.

Moreover, Fine points out, the CAPTEM combination is extremely nontoxic. There were no grade 4 toxicities and only 10-15% grade 3 toxicities, with the most common grade 3 toxicity being lymphopenia.

Read more about this study >>>

<<< View more from the 2014 GI Cancers Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x